

1 We Claim:

2

3 1. A therapeutic composition comprising 0.5 wt % to 65 wt % of a drug
4 orally administrable to a patient and 60 wt % to 99.5 wt % of a polyitol
5 pharmaceutically acceptable carrier for aiding in administering the drug to the
6 patient.

7

8 2. A therapeutic composition comprising 0.5 wt % to 65 wt % of a drug
9 orally administrable to a patient and 60 wt % to 99.5 wt % of a tetritol
10 compatible with the drug as a pharmaceutically acceptable carrier for aiding in
11 administering the drug to the patient.

12

13 3. A therapeutic composition comprising 0.5 wt % to 65 wt % of a drug
14 orally administrable to a patient and 60 wt % to 99.5 wt % of a pentitol
15 compatible with the drug as a pharmaceutically acceptable carrier for aiding in
16 administering the drug to the patient.

17

18 4. A therapeutic composition comprising 0.5 wt % to 65 wt % of a drug
19 orally administrable to a patient and 60 wt % to 99.5 wt % of a hexitol
20 compatible with the drug as a pharmaceutically acceptable carrier for aiding in
21 administering the drug to the patient.

22

23 5. A dosage form for delivering a drug to a patient, wherein the dosage
24 form comprises 0.5 wt % to 65 wt % of a drug orally deliverable to a patient,
25 and 65 wt % to 99.5 wt % of a polyitol compatible with the drug as a
26 pharmaceutically acceptable carrier for the polyitol, for delivering the drug; a
27 wall that surrounds the drug and the polyitol permeable to fluid and
28 impermeable to the drug and polyitol; and an exit in the wall for delivering the
29 drug from the dosage form to the patient.

1 6. A dosage form for delivering a drug to a patient, wherein the dosage
2 form comprises 0.5 wt % to 65 wt % of a drug orally deliverable to a patient
3 and 60 wt % to 99.5 wt % of a tetritol compatible with the drug, as a
4 pharmaceutically carrier for delivering the drug; a wall that surrounds the drug
5 and tetritol permeable to fluid and impermeable to drug and tetritol, and an
6 exit in the wall for delivering the drug from the dosage form to the patient.

7
8 7. A dosage form for delivering a drug to a patient, wherein the dosage
9 form comprises 0.5 wt % to 65 wt % of a drug orally deliverable to a patient
10 and 60 wt % to 99.5 wt % of a pentitol compatible with the drug and serves as
11 a pharmaceutically carrier for drug for delivering the drug; a wall that
12 surrounds the drug and pentitol permeable to fluid and impermeable to drug
13 and pentitol; and an exit in the wall for delivering the drug from the dosage
14 form to the patient.

15
16 8. A dosage form for delivering a drug to a patient, wherein the dosage
17 form comprises 0.5 wt % to 65 wt % of a drug orally deliverable to a patient,
18 and 60 wt % to 99.5 wt % of a hexitol compatible with the drug and operates
19 as a pharmaceutically carrier for delivering the drug; a wall that surrounds the
20 drug and hexitol permeable to the passage of fluid and impermeable to drug
21 and the hexitol; and, an exit in the wall for delivering the drug from the dosage
22 form to the patient.

23
24 9. A dosage form for delivering oxybutynin to a patient, wherein the
25 dosage form comprises 0.5 wt % to 65 wt % of oxybutynin orally deliverable
26 to a patient, and 60 wt % to 99.5 wt % of a hexitol compatible with the
27 oxybutynin that performs as a pharmaceutically acceptable carrier for
28 oxybutynin; a wall that surrounds oxybutynin and hexitol and is permeable to
29 the passage of fluid present in a patient and impermeable to the passage of

1 oxybutynin and hexitol; and, an exit in the wall for delivering oxybutynin from
2 the dosage form to the patient.

3

4 10. The dosage form according to claim 9, wherein the hexitol is mannitol.

5

6 11. The dosage form according to claim 9, wherein oxybutynin is present
7 as oxybutynin hydrochloride.